These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9736785)

  • 1. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice.
    Bijvoet AG; Kroos MA; Pieper FR; Van der Vliet M; De Boer HA; Van der Ploeg AT; Verbeet MP; Reuser AJ
    Hum Mol Genet; 1998 Oct; 7(11):1815-24. PubMed ID: 9736785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II.
    Bijvoet AG; Van Hirtum H; Kroos MA; Van de Kamp EH; Schoneveld O; Visser P; Brakenhoff JP; Weggeman M; van Corven EJ; Van der Ploeg AT; Reuser AJ
    Hum Mol Genet; 1999 Nov; 8(12):2145-53. PubMed ID: 10545593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease.
    Van Hove JL; Yang HW; Wu JY; Brady RO; Chen YT
    Proc Natl Acad Sci U S A; 1996 Jan; 93(1):65-70. PubMed ID: 8552676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cDNA-encoded human acid alpha-glucosidase in milk of transgenic mice.
    Bijvoet AG; Kroos MA; Pieper FR; de Boer HA; Reuser AJ; van der Ploeg AT; Verbeet MP
    Biochim Biophys Acta; 1996 Aug; 1308(2):93-6. PubMed ID: 8764823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human acid alpha-glucosidase corrects acid alpha-glucosidase-deficient human fibroblasts, quail fibroblasts, and quail myoblasts.
    Yang HW; Kikuchi T; Hagiwara Y; Mizutani M; Chen YT; Van Hove JL
    Pediatr Res; 1998 Mar; 43(3):374-80. PubMed ID: 9505277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease type II leads to high level expression of enzyme and corrects glycogen accumulation.
    Nicolino MP; Puech JP; Kremer EJ; Reuser AJ; Mbebi C; Verdière-Sahuqué M; Kahn A; Poenaru L
    Hum Mol Genet; 1998 Oct; 7(11):1695-702. PubMed ID: 9736771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
    Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
    McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
    Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase.
    Fuller M; Van der Ploeg A; Reuser AJ; Anson DS; Hopwood JJ
    Eur J Biochem; 1995 Dec; 234(3):903-9. PubMed ID: 8575451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.
    Raben N; Nagaraju K; Lee A; Lu N; Rivera Y; Jatkar T; Hopwood JJ; Plotz PH
    Transgenic Res; 2003 Apr; 12(2):171-8. PubMed ID: 12739885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy.
    Raben N; Lu N; Nagaraju K; Rivera Y; Lee A; Yan B; Byrne B; Meikle PJ; Umapathysivam K; Hopwood JJ; Plotz PH
    Hum Mol Genet; 2001 Sep; 10(19):2039-47. PubMed ID: 11590121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Pompe's disease with recombinant enzymes].
    Van Hove JL
    Verh K Acad Geneeskd Belg; 1998; 60(4):347-57. PubMed ID: 9883081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and stability of human and bovine acid alpha-glucosidase in cultured fibroblasts and skeletal muscle cells from glycogenosis type II patients.
    Reuser AJ; Kroos MA; Ponne NJ; Wolterman RA; Loonen MC; Busch HF; Visser WJ; Bolhuis PA
    Exp Cell Res; 1984 Nov; 155(1):178-89. PubMed ID: 6237928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of a functional human acid maltase in tobacco seeds: biochemical analysis, uptake by human GSDII cells, and in vivo studies in GAA knockout mice.
    Martiniuk F; Reggi S; Tchou-Wong KM; Rom WN; Busconi M; Fogher C
    Appl Biochem Biotechnol; 2013 Oct; 171(4):916-26. PubMed ID: 23907679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid α-glucosidase.
    Basile I; Da Silva A; El Cheikh K; Godefroy A; Daurat M; Harmois A; Perez M; Caillaud C; Charbonné HV; Pau B; Gary-Bobo M; Morère A; Garcia M; Maynadier M
    J Control Release; 2018 Jan; 269():15-23. PubMed ID: 29108866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.
    Van den Hout JM; Reuser AJ; de Klerk JB; Arts WF; Smeitink JA; Van der Ploeg AT
    J Inherit Metab Dis; 2001 Apr; 24(2):266-74. PubMed ID: 11405345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.